High Throughput Proteomics Systems for Accelerated Profiling of Putative Plasma Biomarkers


At a Glance
  • Status: Completed Consortium
  • Year Launched: 2008
  • Initiating Organization: European Commission
  • Initiator Type: Government
  • Disease focus:
    Cancers
  • Location: Europe

Abstract

The PROACTIVE consortium will through research and innovation develop the multiplexed proximity ligation assay into a high throughput protein detection and quantification technology along with novel data management and analysis tools. Hundreds of putative biomarkers of the plasma proteome can then be assayed with high sensitivity in minute sample volumes, far surpassing any current capabilities. This consortium combines three SMEs across Europe with synergistic competences in technology development, reagent manufacturing, and software development for data management and analysis. Together with clinical cancer scientists, biostatisticians, and diagnostics industry, these high capacity tools will be evaluated in pilot projects for cancer biomarkers using bio-banked samples.

Mission

At the conclusion of this collaborative project, the research and innovation conducted within the consortium will enable the partners to position themselves at the very forefront of high-throughput biomarker research strengthening their competitiveness in the international arena.

The goal of the PROACTIVE consortium was to develop a validated and fully operational high throughput targeted proteomics pipeline for analysis of human blood samples capable of detecting very large sets of putative cancer biomarkers.

Structure & Governance

This consortium is the project of CORDIS (Community Research and Development Information Service), which is a program of the European Commission.

Financing

Funded by the European Commission

Intellectual Property

Work produced by the consortium is owned by the European Commission

Patient Engagement

Implementation of the PROACTIVE system on a cohort of patients with colorectal cancer led to the identification of proteins specific for the early stages of the disease. These constitute putative diagnostic biomarker candidates and subsequent validation will determine their future incorporation into a plasma biomarker service.

Impact/Accomplishment

The consortium’s summary report can be found here

Points of Contact

Olink Bioscience AB
CHEMISTRY BMC - BOX 599
751 24 UPPSALA
Sweden
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative contact : Simon Fredriksson
Tel.: +46 (0)18 - 444 39 84
Fax: -+46 (0)18 - 50 93 00

Sponsors & Partners

Innova Biosciences Limited

Uppsala Universitet

Integromics SL ITG

Kobenhavns Universitet

Fujirebio Diagnostics AB

Olink Bioscience AB


Last Updated: 06/20/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.